Vivimed granted DGHS approval for manufacture, market of Favipiravir Tablets

Hyderabad:  Hyderabad based pharmaceutical company Vivimed Labs Limited on Monday said that it has been granted Government of India (Director General of Health Services ) approval to Manufacture and market Favipiravir Tablet 200 mg & 400 mg under Vivimed’s own brand name “Favulous” across India. Favipiravir is one of the leading oral anti-viral treatments approved in various countries for the potential treatment of patients with mild to moderate Covid-19 disease.

In August 2020, the company had announced manufacturing of Favulous tablets against an export order.

“With huge spike in Covid19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching “Favulous” at a competitive price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with Vivimed’s commitment to be at forefront in India’s fight against Covid-19” Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said.